Safety Check | Harvard Medical School – Harvard Medical School

This article is part of Harvard Medical Schools continuing coverage of medicine, biomedical research, medical education, and policy related to the SARS-CoV-2 pandemic and the disease COVID-19.
Almost immediately after the first mRNA-based COVID-19 vaccines were authorized for emergency use and administered to individuals outside of clinical trials, reports of anaphylaxisa life-threatening whole-body allergic reactionraised widespread concerns among experts and the public.
Now, real world data on…

Click here to view the original article.